Algerian pharmaceutical group Saidal has launched DAPAFLUX, a new medication aimed at managing type 2 diabetes and preventing its cardiovascular and renal complications. The launch was announced at a scientific conference themed "Convergence: A Common Approach," supervised by Saidal's General Director, Younes Bouarara. The event was attended by various high-ranking officials, including the Secretary General of the Ministry of Pharmaceutical Industry, Ouassim Kouidri, and the Director General of the National Agency for Pharmaceutical Products.

The introduction of DAPAFLUX marks a significant milestone in Saidal's development strategy, which focuses on diversifying therapeutic areas, enhancing industrial and technological capabilities, and promoting innovation. The company's General Director emphasized that this launch reaffirms Saidal's commitment to providing high-quality, affordable medications to all patients. This development is particularly crucial given the growing prevalence of type 2 diabetes in Algeria, with 14.4% of adults aged 18-69 affected, according to recent data.

The launch of DAPAFLUX addresses a pressing public health concern, as type 2 diabetes has become a significant health issue in Algeria. The country's Health Minister, Mohamed Seddik Aït Messaoudene, has highlighted the urgency of the situation, noting that nearly one in seven adults is affected by the disease. Moreover, a substantial proportion of those affected remain unaware of their condition due to a lack of screening. This underscores the need for a comprehensive approach to managing the disease.

To combat the growing incidence of type 2 diabetes, the Algerian Ministry of Health has adopted a multi-faceted strategy. This approach focuses on primary prevention through promoting healthy lifestyles, early diagnosis, and improved access to care, medical follow-up, and therapeutic education. As part of this effort, the ministry has recently introduced the 2026 National Guide for Good Practices in Diabetology, which provides a scientific and practical framework for healthcare professionals.

The National Guide for Good Practices in Diabetology is designed to support healthcare professionals at every stage of patient care, from prevention to managing complications. It includes adapted protocols for specific patient profiles, such as children, pregnant women, and the elderly, as well as for special situations like hospitalizations and Ramadan fasting. The guide is expected to enhance the quality of care and promote better health outcomes for patients with type 2 diabetes.

In conjunction with the updated protocols, the Algerian Ministry of Health is emphasizing the importance of human resources and access to proximity care. Recently, 384 general practitioners, trained in diabetology at various medical faculties, have been deployed to public health establishments. These healthcare professionals will play a vital role in bringing medical services closer to the population, particularly in areas with limited access to specialized care.

To further address the issue, public awareness and screening campaigns have been initiated in several regions. These campaigns aim to educate the population about risk factors, provide necessary examinations for exposed individuals, and refer complex cases to specialized structures. The program is expected to expand gradually, with priority given to remote and underserved areas.

Key points

  • Saidal's launch of DAPAFLUX is a significant step in Algeria's fight against type 2 diabetes and its complications.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.